Francoise Brignole-Baudouin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3356377/publications.pdf

Version: 2024-02-01

65 papers

4,835 citations

30 h-index 54 g-index

67 all docs

67 docs citations

67 times ranked

3477 citing authors

#	Article	IF	Citations
1	The Dual Effect of Rho-Kinase Inhibition on Trabecular Meshwork Cells Cytoskeleton and Extracellular Matrix in an In Vitro Model of Glaucoma. Journal of Clinical Medicine, 2022, 11, 1001.	1.0	16
2	Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model. Journal of Neuroinflammation, 2022, 19, 63.	3.1	11
3	Proteomic Analysis of Tears and Conjunctival Cells Collected with Schirmer Strips Using timsTOF Pro: Preanalytical Considerations. Metabolites, 2022, 12, 2.	1.3	16
4	Comparison of Two Experimental Mouse Dry Eye Models through Inflammatory Gene Set Enrichment Analysis Based on a Multiplexed Transcriptomic Approach. International Journal of Molecular Sciences, 2021, 22, 10770.	1.8	4
5	Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time. International Journal of Pharmaceutics, 2020, 574, 118734.	2.6	38
6	Lipid Annotation by Combination of UHPLC-HRMS (MS), Molecular Networking, and Retention Time Prediction: Application to a Lipidomic Study of In Vitro Models of Dry Eye Disease. Metabolites, 2020, 10, 225.	1.3	16
7	In Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics. Pharmaceutics, 2020, 12, 360.	2.0	14
8	Lipidomic analysis of epithelial corneal cells following hyperosmolarity and benzalkonium chloride exposure: New insights in dry eye disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158728.	1.2	14
9	Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients. Ocular Surface, 2019, 17, 516-525.	2.2	21
10	Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations With HLA-DRA and HLA-DRB1. Frontiers in Immunology, 2018, 9, 2271.	2.2	27
11	Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicology in Vitro, 2017, 41, 21-29.	1.1	36
12	Hyperosmolarity and Benzalkonium Chloride Differently Stimulate Inflammatory Markers in Conjunctiva-Derived Epithelial Cells in vitro. Ophthalmic Research, 2017, 58, 40-48.	1.0	27
13	Neuroglobin Can Prevent or Reverse Glaucomatous Progression in DBA/2J Mice. Molecular Therapy - Methods and Clinical Development, 2017, 5, 200-220.	1.8	30
14	Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease., 2017, 58, 2438.		36
15	The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells., 2017, 58, 2406.		79
16	Evaluation of a new concept of immune-enhancing diet in a model of head-injured rat with infectious complications: A proof of concept study. Clinical Nutrition, 2016, 35, 1291-1300.	2.3	6
17	In Vitro Inhibition of NFAT5-Mediated Induction of CCL2 in Hyperosmotic Conditions by Cyclosporine and Dexamethasone on Human HeLa-Modified Conjunctiva-Derived Cells. PLoS ONE, 2016, 11, e0159983.	1.1	22
18	Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. Stem Cell Research and Therapy, 2015, 6, 177.	2.4	70

#	Article	lF	CITATIONS
19	Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments. Current Eye Research, 2015, 40, 40-47.	0.7	7
20	Ocular surface assessment in soft contact lens wearers; the contribution of tear osmolarity among other tests. Acta Ophthalmologica, 2014, 92, 364-369.	0.6	20
21	Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 4039-4049.	1.9	47
22	A new technique of endothelial graft: the femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK). Acta Ophthalmologica, 2013, 91, e497-e499.	0.6	2
23	Reduced in vivo Ocular Surface Toxicity with Polyquad-Preserved Travoprost versus Benzalkonium-Preserved Travoprost or Latanoprost Ophthalmic Solutions. Ophthalmic Research, 2012, 48, 89-101.	1.0	49
24	In Vitro and In Vivo Evaluation of a Preservative-Free Cationic Emulsion of Latanoprost in Corneal Wound Healing Models. Cornea, 2012, 31, 1319-1329.	0.9	31
25	A New Safety Concern for Glaucoma Treatment Demonstrated by Mass Spectrometry Imaging of Benzalkonium Chloride Distribution in the Eye, an Experimental Study in Rabbits. PLoS ONE, 2012, 7, e50180.	1.1	92
26	In Vitro and In Vivo Comparative Toxicological Study of a New Preservative-Free Latanoprost Formulation., 2012, 53, 8172.		39
27	In Vitro Interactions between Peripheral Blood Lymphocytes and the Wong-Kilbourne Derivative of Chang Conjunctival Cells., 2012, 53, 1492.		0
28	Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study. PLoS ONE, 2012, 7, e33913.	1.1	31
29	CXCR3 Antagonism of SDF-1(5-67) Restores Trabecular Function and Prevents Retinal Neurodegeneration in a Rat Model of Ocular Hypertension. PLoS ONE, 2012, 7, e37873.	1.1	26
30	Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Molecular Vision, 2012, 18, 851-63.	1.1	60
31	Comparative <i>In Vitro</i> Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells. Current Eye Research, 2011, 36, 979-988.	0.7	29
32	<i>In Vitro</i> Comparative Toxicology of Polyquad-Preserved and Benzalkonium Chloride-Preserved Travoprost/Timolol Fixed Combination and Latanoprost/Timolol Fixed Combination. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 273-280.	0.6	32
33	Spectrofluorometry assays for oxidative stress and apoptosis, with cell viability on the same microplates: A multiparametric analysis and quality control. Toxicology in Vitro, 2011, 25, 1089-1096.	1.1	11
34	A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmologica, 2011, 89, e591-e597.	0.6	115
35	Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Advances in Therapy, 2011, 28, 311-325.	1.3	40
36	Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. British Journal of Ophthalmology, 2011, 95, 869-875.	2.1	75

#	Article	IF	CITATIONS
37	Switching from a preserved to a preservativeâ€free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmologica, 2010, 88, 329-336.	0.6	124
38	An In Vivo Confocal Microscopy and Impression Cytology Evaluation of Pterygium Activity. Cornea, 2010, 29, 392-399.	0.9	23
39	Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 2010, 29, 312-334.	7.3	787
40	Live Conjunctiva-Associated Lymphoid Tissue Analysis in Rabbit under Inflammatory Stimuli Using In Vivo Confocal Microscopy. , 2010, 51, 1008.		24
41	Multiple Endpoint Analysis of the 3D-Reconstituted Corneal Epithelium after Treatment with Benzalkonium Chloride: Early Detection of Toxic Damage. , 2009, 50, 1644.		111
42	The Ocular Surface of Glaucoma Patients Treated over the Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and T-Helper 2 Pathways. Ophthalmology, 2008, 115, 109-115.	2.5	179
43	In VivoConfocal Microscopic Grading System for Standardized Corneal Evaluation: Application to Toxic-Induced Damage in Rat. Current Eye Research, 2008, 33, 826-838.	0.7	10
44	<i>In Vitro</i> Effects of Preservative-Free Tafluprost and Preserved Latanoprost, Travoprost, and Bimatoprost in a Conjunctival Epithelial Cell Line. Current Eye Research, 2008, 33, 303-312.	0.7	86
45	In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost. , 2007, 48, 4123.		111
46	Th1 and Th2 Responses on the Ocular Surface in Uveitis Identified by CCR4 and CCR5 Conjunctival Expression. American Journal of Ophthalmology, 2007, 144, 580-585.e2.	1.7	16
47	New Tools for the Evaluation of Toxic Ocular Surface Changes in the Rat. , 2007, 48, 5473.		107
48	Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFNI ³ and toxicological profiles. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 534-546.	1.0	22
49	Comparison of Toxicological Profiles of Benzalkonium Chloride and Polyquaternium-1: An Experimental Study. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 267-278.	0.6	109
50	Fluoroquinolone Eye Drop–Induced Cytotoxicity: Role of Preservative in P2X7 Cell Death Receptor Activation and Apoptosis. , 2006, 47, 2812.		54
51	Comparative Anatomy of Laboratory Animal Corneas with a New-Generation High-ResolutionIn VivoConfocal Microscope. Current Eye Research, 2006, 31, 501-509.	0.7	55
52	Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 531-538.	1.0	81
53	In Vitro Comparison of Cytoprotective and Antioxidative Effects of Latanoprost, Travoprost, and Bimatoprost on Conjunctiva-Derived Epithelial Cells., 2005, 46, 4594.		98
54	In Vitro Study of Inflammatory Potential and Toxicity Profile of Latanoprost, Travoprost, and Bimatoprost in Conjunctiva-Derived Epithelial Cells., 2005, 46, 2444.		162

#	Article	IF	CITATIONS
55	CCR4 and CCR5 expression in conjunctival specimens as differential markers of TH1/ TH2 in ocular surface disorders. Journal of Allergy and Clinical Immunology, 2005, 116, 614-619.	1.5	70
56	Conjunctival Proinflammatory and Proapoptotic Effects of Latanoprost and Preserved and Unpreserved Timolol: An Ex Vivo and In Vitro Study. Investigative Ophthalmology and Visual Science, 2004, 45, 1360-1368.	3.3	250
57	Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Experimental Eye Research, 2004, 78, 473-481.	1.2	78
58	Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology, 2004, 111, 2186-2192.	2.5	185
59	In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 1037-1043.	1.0	71
60	Clinical and biologic features of CD4+CD56+ malignancies. Blood, 2002, 99, 1556-1563.	0.6	404
61	Ocular Surface Changes Induced by Contact Lens Wear. Cornea, 2001, 20, 820-825.	0.9	86
62	Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology, 2000, 107, 1841-1849.	2.5	155
63	Expression of Fas-Fas Ligand Antigens and Apoptotic Marker APO2.7 by the Human Conjunctival Epithelium. Positive Correlation with Class II HLA DR Expression in Inflammatory Ocular Surface Disorders. Experimental Eye Research, 1998, 67, 687-697.	1.2	70
64	Immunophenotyping of human dendriform cells from the conjunctival epithelium. Current Eye Research, 1997, 16, 475-481.	0.7	28
65	Growth Factors in Vitreous and Subretinal Fluid Cells from Patients with Proliferative Vitreoretinopathy. Ophthalmic Research, 1993, 25, 52-59.	1.0	90